Similar articles

• mTOR inhibition and adult T-cell leukemia.

  Hirase C, Maeda Y, Yamaguchi T, Miyatake J, Kanamaru A. Hirase C, et al. Leuk Lymphoma. 2009 Apr;50(4):645-7. doi: 10.1080/10428190802709446. Leuk Lymphoma. 2009. PMID: 19373664 No abstract available.
• Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

  Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H. Ikezoe T, et al. Leuk Res. 2007 May;31(5):673-82. doi: 10.1016/j.leukres.2006.08.001. Epub 2006 Sep 27. Leuk Res. 2007. PMID: 17007924
• Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

  Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA. Batista A, et al. Exp Hematol. 2011 Apr;39(4):457-472.e3. doi: 10.1016/j.exphem.2011.01.005. Epub 2011 Jan 26. Exp Hematol. 2011. PMID: 21277936
• [Advances on PI3K/Akt/mTOR signalling pathway in malignancies].

  Yu BH, Zhou XY. Yu BH, et al. Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):674-6. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 16536284 Review. Chinese. No abstract available.
• New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.

  Carraway H, Hidalgo M. Carraway H, et al. Breast Cancer Res. 2004;6(5):219-24. doi: 10.1186/bcr927. Epub 2004 Aug 12. Breast Cancer Res. 2004. PMID: 15318929 Free PMC article. Review.